在m-health应用程序中有效的行为改变技术支持在2型糖尿病患者中进行血糖控制的干预:随机对照试验的元分析和元回归分析
1Academy of Medical Engineering and Translational Medicine, Tianjin University, Tianjin, China.
Digital health
|March 17, 2025
概括
移动健康应用程序有效地改善血糖控制和其他健康结果. 行为改变技术的组合,如"反和监测"和"社会支持",显示最有希望的增强患者的结果.
科学领域:
- 数字健康数字健康
- 行为科学 行为科学
- 代谢健康 代谢健康
背景情况:
- 移动健康 (m-health) 应用程序越来越多地用于健康干预.
- 行为改变技术 (BCT) 是有效的健康干预措施的关键组成部分.
- 血糖控制仍然是患者健康管理的一个重大挑战.
研究的目的:
- 评估m-health应用程序支持的干预措施对患者健康结果的有效性.
- 识别和分析在这些干预中使用的行为改变技术 (BCT).
- 为了确定有效的BCT或组合来改善血糖控制.
主要方法:
- 来自MEDLINE,EMBASE和Web of Science数据库的43项随机对照试验 (RCT) 的系统审查.
- 使用随机效应模型对健康结果的元分析,包括血红蛋白A1c (HbA1c).
- 超回归来评估BCT和HbA1c改善之间的关联;使用Cochrane协作工具评估偏差风险.
主要成果:
- 通过M-health干预,显著降低了HbA1c,血糖,血压,胆固醇,甘油三,体重和腰围.
- 干预使用了平均5.77个BCT,其中"可信来源"和"社会支持"是最常见的.
- "反和监测"",社会支持"和"结果比较"的组合是糖血控制中最简单和最有效的.
结论:
- 使用特定的BCT的M-health应用程序为改善血糖控制和整体健康提供了可行的策略.
- "解决问题"和"奖励和威胁"的BCT与更大的HbA1c降低有关.
- 建议进一步研究详细的BCT报告和实验设计,如多相优化策略.
更多相关视频
相关概念视频
Diabetes: Management and Pharmacotherapy
220
The therapy for diabetes aims to alleviate hyperglycemia-related symptoms, prevent acute metabolic decompensation, and reduce chronic end-organ complications. Glycemic control is evaluated through short-term (self-monitoring, continuous glucose monitoring) and long-term (A1c, fructosamine) metrics, enabling near real-time tracking of blood glucose levels and reflecting glycemic control over specific time frames.
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
Insulin remains the cornerstone of treatment for most patients with type 1 and many...
220
Stress Prevention and Stress Management Techniques VI
25
Adopting a healthier lifestyle often requires overcoming significant challenges, but leveraging psychological, social, and cultural resources can facilitate meaningful change. Effective self-change hinges on understanding and applying key tools such as motivation and goal setting, which help sustain efforts toward long-term health benefits.
Motivation and Self-Determination
Motivation, the driving force behind behavior, plays a pivotal role at every stage of the change process. The research...
Motivation and Self-Determination
Motivation, the driving force behind behavior, plays a pivotal role at every stage of the change process. The research...
25
Diabetes Mellitus: Type 2 and Gestational
2.1K
Type 2 diabetes, characterized by insulin resistance, arises when the insulin receptors on cells lose responsiveness to insulin, diminishing the cell's capacity to take up glucose, resulting in elevated blood glucose levels. To receive a diagnosis of Type 2 diabetes, a series of blood glucose tests are necessary to assess whether the blood glucose falls within normal parameters. If the result is out of the normal range, a patient may be diagnosed as prediabetic or diabetic, depending on the...
2.1K
Oral Hypoglycemic Agents: Biguanides and Glitazones
148
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
148
Diabetes Mellitus: Overview and Type I Subtype
2.3K
Diabetes mellitus is a chronic metabolic disorder characterized by high blood glucose levels due to inadequate insulin production, insulin resistance, or both. The condition affects millions worldwide and can significantly impact their health and quality of life.
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
Type 1 diabetes is an autoimmune disease in which the immune system mistakenly attacks and destroys the insulin-producing beta cells in the pancreas. As a result, the body is unable to produce sufficient insulin, and individuals with...
2.3K
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
140
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
140


